Point72 (DIFC)’s Cartesian Therapeutics RNAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-1,725
Closed -$46.6K 1769
2024
Q2
$46.6K Buy
+1,725
New +$41.2K ﹤0.01% 1105

Other funds holding RNAC

Point72 (DIFC)'s RNAC Position: Q3 2024 in Review

Point72 (DIFC) sold out of Cartesian Therapeutics (RNAC) in Q3 2024, closing a stake of 1,725 shares — an estimated $46.6K sold.

Point72 (DIFC) first reported a position in RNAC in Q2 2024 and held it in 1 quarter. The position peaked at $46.6K in Q2 2024. 64 funds tracked by Wall St. Rank hold RNAC as of Q3 2024.

  • Point72 (DIFC) reported no remaining Cartesian Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Point72 (DIFC) sold 1,725 Cartesian Therapeutics shares in Q3 2024, an estimated $46.6K.
  • Point72 (DIFC) first reported a position in Cartesian Therapeutics in Q2 2024 and held it in 1 quarter.
  • Point72 (DIFC)'s Cartesian Therapeutics position peaked at $46.6K in Q2 2024.
  • 64 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2024.

Based on Point72 (DIFC)'s 13F filing for Q3 2024, filed 14 Nov 2024.